(Q24236290)

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Treatment perspectives for human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Sleeping sickness surveillance: an essential step towards elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Treatment of human African trypanosomiasis--present situation and needs for research and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

The epidemiology and control of human African trypanosomiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Eliminating human African trypanosomiasis: where do we stand and what comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

Waking up to sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Eflornithine for the treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Melarsen in the treatment of Trypanosoma gambiense infection in man.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Four years' experience of melarsen oxide/BAL in the treatment of late-stage Rhodesian sleeping sickness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Clinical trials of diamidine in Rhodesian sleeping sickness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

The treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021

Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006201.PUB2

7 January 2021